NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9, 2023, at 3:55 p.m. ET.
Rain Oncology Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on Thursday, February 9, 2023, at 3:55 p.m. ET, being held in New York, NY.
A live webcast of the fireside chat can be accessed here. A replay of the event will be available on the "Events" section of the Rain website after the conclusion of the event and will be archived on the Rain website at .
About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of the p53-MDM2 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com
加利福尼亚州纽瓦克,2023年1月31日(环球通讯社)--在今天早些时候由Rain Oncology(纳斯达克:RAIN)发布的一份新闻稿中,该公司将其演示文稿的日期和时间更新为2023年2月9日(星期四)下午3点55分。Et.
Rain Oncology Inc.(纳斯达克股票代码:RAIN)是一家以其主要候选产品Milademetan开发精确肿瘤疗法的后期公司,Milademetan是一种口服小分子抑制P53-MDM2复合体的药物,可重新激活P53。该公司今天宣布,Rain首席执行官Avanish Vellanki将参加2023年2月9日(星期四)下午3:55举行的Guggenheim Healthcare Talks肿瘤学日会议的炉边聊天。ET,正在纽约州纽约举行。
可以在这里观看炉边聊天的现场网络直播。活动结束后,可在Rain网站的“Events”栏目上看到活动的重播,并将在Rain网站上存档。
关于Rain Oncology Inc.
Rain Oncology Inc.是一家晚期精准肿瘤学公司,正在开发针对致癌驱动因素的疗法,以选择它认为最有可能受益的基因选择的患者。这种方法包括使用肿瘤不可知策略,根据肿瘤的潜在遗传学而不是组织学来选择患者。Rain的主要候选产品Milademetan是一种小分子口服P53-MDM2复合体抑制剂,可重新激活P53。除了Milademetan,Rain还在开发一项临床前计划,重点是通过抑制RAD52来诱导癌细胞的合成杀伤力。
媒体联系人
乔丁·坦佩拉托
生活科学传播
邮箱:jtemato@lifescicomms.com
投资者联系方式
丹·费里
LifeSci顾问
+1.617.430.7576
邮箱:Daniel@lifescivisors.com。